Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue

Detalhes bibliográficos
Autor(a) principal: Oliveira, Fernanda Cerqueira Barroso de
Data de Publicação: 2022
Outros Autores: Bauer, Eduarda Jacinto, Ribeiro, Carolina Martins, Pereira, Sidney Alcântara, Beserra, Bruna T. S., Wajner, Simone Magagnin, Maia, Ana Luiza Silva, Neves, Francisco de Assis Rocha, Coelho, Michella S., Amato, Angélica Amorim
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/259238
Resumo: Aims: Liraglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist used as an anti-hyperglycemic agent in type 2 diabetes treatment and recently approved for obesity management. Weight loss is attributed to appetite suppression, but therapy may also increase energy expenditure. To further investigate the effect of GLP-1 signaling in thermogenic fat, we assessed adipose tissue oxygen consumption and type 2 deiodinase (D2) activity in mice treated with liraglutide, both basally and after β3-adrenergic treatment. Methods: Male C57BL/6J mice were randomly assigned to receive liraglutide (400 μg/kg, n=12) or vehicle (n=12). After 16 days, mice in each group were co-treated with the selective β3-adrenergic agonist CL316,243 (1 mg/kg, n=6) or vehicle (n=6) for 5 days. Adipose tissue depots were assessed for gene and protein expression, oxygen consumption, and D2 activity. Results: Liraglutide increased interscapular brown adipose tissue (iBAT) oxygen consumption and enhanced β3-adrenergic-induced oxygen consumption in iBAT and inguinal white adipose tissue (ingWAT). These effects were accompanied by upregulation of UCP-1 protein levels in iBAT and ingWAT. Notably, liraglutide increased D2 activity without significantly upregulating its mRNA levels in iBAT and exhibited additive effects to β3-adrenergic stimulation in inducing D2 activity in ingWAT. Conclusions: Liraglutide exhibits additive effects to those of β3-adrenergic stimulation in thermogenic fat and increases D2 activity in BAT, implying that it may activate this adipose tissue depot by increasing intracellular thyroid activation, adding to the currently known mechanisms of GLP-1A-induced weight loss.
id UFRGS-2_eaed64fa167cc0bb05e00d443e56beda
oai_identifier_str oai:www.lume.ufrgs.br:10183/259238
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Oliveira, Fernanda Cerqueira Barroso deBauer, Eduarda JacintoRibeiro, Carolina MartinsPereira, Sidney AlcântaraBeserra, Bruna T. S.Wajner, Simone MagagninMaia, Ana Luiza SilvaNeves, Francisco de Assis RochaCoelho, Michella S.Amato, Angélica Amorim2023-06-21T03:31:26Z20221664-2392http://hdl.handle.net/10183/259238001168604Aims: Liraglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist used as an anti-hyperglycemic agent in type 2 diabetes treatment and recently approved for obesity management. Weight loss is attributed to appetite suppression, but therapy may also increase energy expenditure. To further investigate the effect of GLP-1 signaling in thermogenic fat, we assessed adipose tissue oxygen consumption and type 2 deiodinase (D2) activity in mice treated with liraglutide, both basally and after β3-adrenergic treatment. Methods: Male C57BL/6J mice were randomly assigned to receive liraglutide (400 μg/kg, n=12) or vehicle (n=12). After 16 days, mice in each group were co-treated with the selective β3-adrenergic agonist CL316,243 (1 mg/kg, n=6) or vehicle (n=6) for 5 days. Adipose tissue depots were assessed for gene and protein expression, oxygen consumption, and D2 activity. Results: Liraglutide increased interscapular brown adipose tissue (iBAT) oxygen consumption and enhanced β3-adrenergic-induced oxygen consumption in iBAT and inguinal white adipose tissue (ingWAT). These effects were accompanied by upregulation of UCP-1 protein levels in iBAT and ingWAT. Notably, liraglutide increased D2 activity without significantly upregulating its mRNA levels in iBAT and exhibited additive effects to β3-adrenergic stimulation in inducing D2 activity in ingWAT. Conclusions: Liraglutide exhibits additive effects to those of β3-adrenergic stimulation in thermogenic fat and increases D2 activity in BAT, implying that it may activate this adipose tissue depot by increasing intracellular thyroid activation, adding to the currently known mechanisms of GLP-1A-induced weight loss.application/pdfengFrontiers in endocrinology. Lausanne. Vol. 12 (Jan. 2022), artigo 803363, 11 p.Tecido adiposoAgonistas de receptores adrenérgicos beta 3Peptídeos semelhantes ao glucagonIodeto peroxidaseLiraglutidaGLP-1 receptor agonistAdipose tissueLiraglutideType 2 deiodinaseβ3-adrenergic stimulationLiraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissueEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001168604.pdf.txt001168604.pdf.txtExtracted Texttext/plain47196http://www.lume.ufrgs.br/bitstream/10183/259238/2/001168604.pdf.txtb1a9a341539670939deecb069163fdc4MD52ORIGINAL001168604.pdfTexto completo (inglês)application/pdf5371683http://www.lume.ufrgs.br/bitstream/10183/259238/1/001168604.pdf4a2c533e755675fb6393405e1ebeb7a1MD5110183/2592382023-06-22 03:31:02.790248oai:www.lume.ufrgs.br:10183/259238Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-06-22T06:31:02Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue
title Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue
spellingShingle Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue
Oliveira, Fernanda Cerqueira Barroso de
Tecido adiposo
Agonistas de receptores adrenérgicos beta 3
Peptídeos semelhantes ao glucagon
Iodeto peroxidase
Liraglutida
GLP-1 receptor agonist
Adipose tissue
Liraglutide
Type 2 deiodinase
β3-adrenergic stimulation
title_short Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue
title_full Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue
title_fullStr Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue
title_full_unstemmed Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue
title_sort Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue
author Oliveira, Fernanda Cerqueira Barroso de
author_facet Oliveira, Fernanda Cerqueira Barroso de
Bauer, Eduarda Jacinto
Ribeiro, Carolina Martins
Pereira, Sidney Alcântara
Beserra, Bruna T. S.
Wajner, Simone Magagnin
Maia, Ana Luiza Silva
Neves, Francisco de Assis Rocha
Coelho, Michella S.
Amato, Angélica Amorim
author_role author
author2 Bauer, Eduarda Jacinto
Ribeiro, Carolina Martins
Pereira, Sidney Alcântara
Beserra, Bruna T. S.
Wajner, Simone Magagnin
Maia, Ana Luiza Silva
Neves, Francisco de Assis Rocha
Coelho, Michella S.
Amato, Angélica Amorim
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Oliveira, Fernanda Cerqueira Barroso de
Bauer, Eduarda Jacinto
Ribeiro, Carolina Martins
Pereira, Sidney Alcântara
Beserra, Bruna T. S.
Wajner, Simone Magagnin
Maia, Ana Luiza Silva
Neves, Francisco de Assis Rocha
Coelho, Michella S.
Amato, Angélica Amorim
dc.subject.por.fl_str_mv Tecido adiposo
Agonistas de receptores adrenérgicos beta 3
Peptídeos semelhantes ao glucagon
Iodeto peroxidase
Liraglutida
topic Tecido adiposo
Agonistas de receptores adrenérgicos beta 3
Peptídeos semelhantes ao glucagon
Iodeto peroxidase
Liraglutida
GLP-1 receptor agonist
Adipose tissue
Liraglutide
Type 2 deiodinase
β3-adrenergic stimulation
dc.subject.eng.fl_str_mv GLP-1 receptor agonist
Adipose tissue
Liraglutide
Type 2 deiodinase
β3-adrenergic stimulation
description Aims: Liraglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist used as an anti-hyperglycemic agent in type 2 diabetes treatment and recently approved for obesity management. Weight loss is attributed to appetite suppression, but therapy may also increase energy expenditure. To further investigate the effect of GLP-1 signaling in thermogenic fat, we assessed adipose tissue oxygen consumption and type 2 deiodinase (D2) activity in mice treated with liraglutide, both basally and after β3-adrenergic treatment. Methods: Male C57BL/6J mice were randomly assigned to receive liraglutide (400 μg/kg, n=12) or vehicle (n=12). After 16 days, mice in each group were co-treated with the selective β3-adrenergic agonist CL316,243 (1 mg/kg, n=6) or vehicle (n=6) for 5 days. Adipose tissue depots were assessed for gene and protein expression, oxygen consumption, and D2 activity. Results: Liraglutide increased interscapular brown adipose tissue (iBAT) oxygen consumption and enhanced β3-adrenergic-induced oxygen consumption in iBAT and inguinal white adipose tissue (ingWAT). These effects were accompanied by upregulation of UCP-1 protein levels in iBAT and ingWAT. Notably, liraglutide increased D2 activity without significantly upregulating its mRNA levels in iBAT and exhibited additive effects to β3-adrenergic stimulation in inducing D2 activity in ingWAT. Conclusions: Liraglutide exhibits additive effects to those of β3-adrenergic stimulation in thermogenic fat and increases D2 activity in BAT, implying that it may activate this adipose tissue depot by increasing intracellular thyroid activation, adding to the currently known mechanisms of GLP-1A-induced weight loss.
publishDate 2022
dc.date.issued.fl_str_mv 2022
dc.date.accessioned.fl_str_mv 2023-06-21T03:31:26Z
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/259238
dc.identifier.issn.pt_BR.fl_str_mv 1664-2392
dc.identifier.nrb.pt_BR.fl_str_mv 001168604
identifier_str_mv 1664-2392
001168604
url http://hdl.handle.net/10183/259238
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Frontiers in endocrinology. Lausanne. Vol. 12 (Jan. 2022), artigo 803363, 11 p.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/259238/2/001168604.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/259238/1/001168604.pdf
bitstream.checksum.fl_str_mv b1a9a341539670939deecb069163fdc4
4a2c533e755675fb6393405e1ebeb7a1
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1801225089392312320